Month: September 2017

The team at Genxys is excited to announce that Post-Myocardial Infarction (Heart Attack) and Smoking Cessation are now covered in TreatGxPlus (pharmacogenetic test and decision support system). Post-Myocardial Infarction (Heart Attack) A myocardial infarction (MI) is also known as a heart…

The TreatGxPlus pharmacogenetic test was developed using an evidence-based approach, following a rigorous review process of scientific studies and professional guidelines. This process allows us to select genetic variants with strong evidence for a significant clinical outcome indicating a change in…